AVDL
Avadel Pharmaceuticals plc (AVDL) Business Model Analysis (2026)
Overall Score
Revenue Model
AVDL remains a high-gross-margin business with gross profit margin at 95.5% TTM, supporting a strong core revenue model.
Revenue efficiency is still solid with asset turnover at 0.99x and revenue per share of 2.04 TTM, but monetization remains modest relative to valuation.
Profitability
Operating profitability is still thin, with EBIT margin at 4.4% and operating margin at 3.9% TTM.
Net margin remains low at 2.4% TTM despite strong gross margin, indicating meaningful operating expense pressure.
Cash Generation
Cash conversion remains acceptable, with operating cash flow margin at 14.0% and free cash flow nearly equal to operating cash flow (FCF/OCF ratio 99.3%).
Free cash flow yield is still low at 1.3% TTM, limiting cash-return support for the business model.
Balance Sheet
Liquidity remains solid with a current ratio of 2.76x and quick ratio of 2.37x TTM.
Leverage is manageable, with debt-to-equity at 0.38x and net debt to EBITDA still negative at -3.62x, indicating a net cash position.
Capital Efficiency
Returns remain modest, with ROIC at 5.7% and ROE at 5.4% TTM.
Working-capital efficiency is weak, as the cash conversion cycle is still very long at 540 days, reflecting heavy inventory and payables distortions.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Avadel Pharmaceuticals plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

